Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 11/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 11/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | ROS1 | P08922 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979938 | 0.84 | RAF1 (0.38) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL2892341 | 0.84 | RAF1 (0.42) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL13230561 | 0.84 | KDR (0.56) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL1435646 | 0.81 | HCAR3 (0.43) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL4202008 | 0.76 | RAF1 (0.44) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL13559611 | 0.75 | P2RX3 (0.41) | RAF1EPHX2KDRBRAFMAPK14 | |
| SCHEMBL12329785 | 0.75 | NR4A1 (0.45) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL12852960 | 0.74 | RAF1 (0.54) | RAF1EPHX2KDRABL1BRAF | |
| SCHEMBL13218159 | 0.74 | KDR (0.36) | KDRBRAF | |
| SCHEMBL2892469 | 0.73 | RAF1 (0.39) | RAF1EPHX2KDRBRAFAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG | 2012-12-06 | — | — | US | disclosed |
| US-8299108-B2 | for treatment of hematological/hormone-dependent cancer | NOVARTIS AG (CH) | 2012-10-30 | — | — | US | disclosed |
| US-8202998-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7767820-B2 | Substituted benzimidazoles and methods of preparation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-7732465-B2 | Substituted benzimidazoles and methods of their use | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-06-08 | — | — | US | disclosed |
| US-20100040677-A1 | FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20080287682-A1 | Substituted benzimidazoles and methods of preparation | NOVARTIS AG | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256375-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF PREPARATION | ABL1, CDK2, KIT | RAF1 73/4885EPHX2 2695/4885KDR 622/4885 |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | RAF1 874/4885EPHX2 2759/4885KDR 2799/4885 |
| US-20100040677-A1 | FORMULATIONS FOR BENZIMIDAZOLYL PYRIDYL ETHERS | PIR, TP53RK, ALK | RAF1 636/4885EPHX2 2076/4885KDR 2198/4885 |
| US-20100234394-A1 | SUBSTITUTED BENZIMIDAZOLES AND METHODS OF THEIR USE | BRAF, DSTYK, CHEK2 | RAF1 57/4885EPHX2 4169/4885KDR 1325/4885 |
| US-20100168060-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | RAF1 874/4885EPHX2 2759/4885KDR 2799/4885 |
| US-20090170904-A1 | Substituted benzimidazoles and methods of their use | BRAF, DSTYK, CHEK2 | RAF1 57/4885EPHX2 4169/4885KDR 1325/4885 |
| US-20080287682-A1 | Substituted benzimidazoles and methods of preparation | ABL1, CDK2, KIT | RAF1 73/4885EPHX2 2695/4885KDR 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.